Travere Therapeutics' Enterprise Value rose 95.36% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 102.66%. This contributed to the annual value of $1.3 billion for FY2024, which is 110.74% up from last year.
Per Travere Therapeutics' latest filing, its Enterprise Value stood at $2.0 billion for Q3 2025, which was up 62.97% from $1.2 billion recorded in Q2 2025.
Over the past 5 years, Travere Therapeutics' Enterprise Value peaked at $2.0 billion during Q3 2025, and registered a low of $526.4 million during Q3 2023.
Moreover, its 3-year median value for Enterprise Value was $1.1 billion (2023), whereas its average is $1.1 billion.
As far as peak fluctuations go, Travere Therapeutics' Enterprise Value tumbled by 63.05% in 2023, and later skyrocketed by 181.22% in 2025.
Over the past 5 years, Travere Therapeutics' Enterprise Value (Quarterly) stood at $1.7 billion in 2021, then declined by 25.76% to $1.3 billion in 2022, then plummeted by 52.06% to $617.4 million in 2023, then spiked by 110.74% to $1.3 billion in 2024, then skyrocketed by 95.36% to $2.0 billion in 2025.
Its last three reported values are $2.0 billion in Q3 2025, $1.2 billion for Q2 2025, and $1.5 billion during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value